Literature DB >> 2104082

The absorption of bismuth and salicylate from oral doses of Pepto-Bismol (bismuth salicylate).

C U Nwokolo1, P Mistry, R E Pounder.   

Abstract

Plasma bismuth and plasma salicylate concentrations were measured before and after three 30-ml oral doses of bismuth salicylate (Pepto-Bismol liquid) in 10 fasting healthy subjects. From 0 to 120 min following the first dose of bismuth salicylate, the plasma bismuth concentration was less than 1 ng/ml. The peak median plasma bismuth concentration was at +240 min (1.7 ng/ml; range 0.8-5.3 ng/ml). Salicylate appeared in the plasma of all subjects at +30 min, and it reached a peak at +120 min (median 61 mg/L; range 46-104 mg/L). The study demonstrates that, despite rapid and substantial absorption of salicylate, there is negligible absorption of bismuth into the bloodstream from standard oral doses of bismuth salicylate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2104082     DOI: 10.1111/j.1365-2036.1990.tb00461.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

1.  D-penicillamine does not increase urinary bismuth excretion in patients treated with tripotassium dicitrato bismuthate.

Authors:  C U Nwokolo; R E Pounder
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

Review 2.  Review: amino acid domains involved in constitutive activation of G-protein-coupled receptors.

Authors:  P J Pauwels; T Wurch
Journal:  Mol Neurobiol       Date:  1998       Impact factor: 5.590

3.  Prevalence of Helicobacter pylori seropositivity among patients undergoing bariatric surgery: a preliminary study.

Authors:  Tolga Erim; Marcia R Cruz-Correa; Samuel Szomstein; Evelio Velis; Raul Rosenthal
Journal:  World J Surg       Date:  2008-09       Impact factor: 3.352

4.  Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB).

Authors:  L F Lacey; N M Frazer; O N Keene; J T Smith
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.